We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Blood-Based Markers Tied to Brain Cell and Memory Loss

By LabMedica International staff writers
Posted on 27 Apr 2021
Print article
Image: The Simoa HD-1 Analyzer (Photo courtesy of Quanterix)
Image: The Simoa HD-1 Analyzer (Photo courtesy of Quanterix)
Previous studies have linked elevated levels of plasma total tau and neurofilament light chain (NfL) with worse cognition and neuroimaging measures of cortical thickness, cortical atrophy, white matter hyperintensity, or white matter integrity.

Neurodegeneration, or brain cell loss, is characteristic of many disorders including Alzheimer's disease, vascular dementia, and Lewy body dementia. Causes and location of neurodegeneration in the brain vary with disease. In Alzheimer's disease, amyloid plaques and neurofibrillary tangles contribute to neurodegeneration and there tends to initially be more brain cell loss in the temporal lobe. In vascular-related cognitive impairment, infarct, white matter hyperintensities, and microbleeds can contribute to cognitive changes.

Neurologists at the Mayo Clinic (Rochester, MN) and their colleagues included 995 participants without dementia who were enrolled in the Mayo Clinic Study on Aging. All had concurrent plasma NfL and Total-tau, cognitive status, and neuroimaging data. Follow-up was repeated approximately every 15 months for a median of 6.2 years. Plasma NfL and T-tau were measured on the Simoa HD-1 Platform (Quanterix, Billerica, MA, USA).

The scientists reported that baseline plasma NfL, compared to T-tau, was more strongly associated with cognitive and neuroimaging outcomes in all analyses. The combination of having both elevated NfL and T-tau at baseline, however, was more strongly associated at cross-section with worse global cognition and memory and with neuroimaging measures including temporal cortex thickness and increased number of infarcts. Longitudinally, T-tau did not add to the prognostic value of NfL. Analyses using Alzheimer's Disease Neuroimaging Initiative (ADNI) had similar result.

Michelle M. Mielke, PhD, a Professor and a senior author of the study, said, “For prognosis purposes, neurofilament light better predicted the rate of neurodegeneration and cognitive decline, regardless of what the cause of neurodegeneration might be. NfL also may help determine how fast someone declines and how effective future therapies might be in slowing this decline.”

The authors concluded that overall, plasma NfL had better utility as a prognostic marker of cognitive decline and neuroimaging changes. Plasma T-tau adds cross-sectional value to NfL in specific contexts. The study was presented on April 18, 2021 at the American Academy of Neurology annual meeting.

Related Links:
Mayo Clinic
Quanterix


New
Gold Supplier
COVID-19 Self-Test
COVID-19 Antigen Test Kit (Colloidal Gold)
New
Gold Supplier
SARS-CoV2 Antigen Rapid Test
SARS-CoV2 Antigen Rapid Test
New
Sepsis Detection Test
SeptiCyte RAPID
New
Silver Supplier
Remote Lab Review Software
CellaVision Remote Review Software

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.